Roca-Fernández Adriana, Dennis Andrea, Nicholls Rowan, McGonigle John, Kelly Matthew, Banerjee Rajarshi, Banerjee Amitava, Sanyal Arun J
Perspectum Ltd., Oxford, United Kingdom.
University College London Hospitals National Health Service Trust, London, United Kingdom.
Front Med (Lausanne). 2021 Mar 29;8:636637. doi: 10.3389/fmed.2021.636637. eCollection 2021.
Obesity is a risk factor for SARS-COV2 infection and is often associated with hepatic steatosis. The aim of this study was to determine if pre-existing hepatic steatosis affects the risk of infection and severity for COVID-19. Prospective cohort study (UK Biobank). Univariate and stepwise multivariate logistic regression analyses were performed on liver phenotypic biomarkers to determine if these variables increased risk of testing positive and being hospitalized for COVID-19; then compared to previously described risk factors associated with COVID-19, including age, ethnicity, gender, obesity, socio-economic status. UK biobank study. 502,506 participants (healthy at baseline) in the UK Biobank, of whom 41,791 underwent MRI (aged 50-83) for assessment of liver fat, liver fibro-inflammatory disease, and liver iron. Positive COVID-19 test was determined from UK testing data, starting in March 2020 and censored in January 2021. Liver fat measured as proton density fat fraction (PDFF%) MRI and body mass index (BMI, Kg/m) to assess prior to February 2020 using MRI of the liver to assess hepatic steatosis. Within the imaged cohort ( = 41, 791), 4,458 had been tested and 1,043 (2.49% of the imaged population) tested positive for COVID-19. Individuals with fatty liver (≥10%) were at increased risk of testing positive (OR: 1.35, = 0.007) and those participants with obesity and fatty liver, were at increased risk of hospitalization with a positive test result by 5.14 times ( = 0.0006). UK Biobank data revealed obese individuals with fatty liver disease were at increased risk of infection and hospitalization for COVID-19. Public policy measures and personalized medicine should be considered in order to protect these high-risk individuals.
肥胖是感染新型冠状病毒的一个风险因素，且常与肝脂肪变性相关。本研究的目的是确定预先存在的肝脂肪变性是否会影响新型冠状病毒肺炎（COVID-19）的感染风险和严重程度。前瞻性队列研究（英国生物银行）。对肝脏表型生物标志物进行单变量和逐步多变量逻辑回归分析，以确定这些变量是否会增加COVID-19检测呈阳性和住院的风险；然后与先前描述的与COVID-19相关的风险因素进行比较，包括年龄、种族、性别、肥胖、社会经济地位。英国生物银行研究。英国生物银行中有502,506名参与者（基线时健康），其中41,791人接受了磁共振成像（MRI）（年龄在50 - 83岁之间），以评估肝脏脂肪、肝脏纤维炎症性疾病和肝脏铁含量。COVID-19检测呈阳性是根据英国的检测数据确定的，始于2020年3月，并于2021年1月进行审查筛选。使用肝脏MRI在2020年2月之前测量质子密度脂肪分数（PDFF%）MRI和体重指数（BMI，kg/m）来评估肝脏脂肪，以评估肝脂肪变性。在成像队列（n = 41,791）中，4,458人接受了检测，1,043人（占成像人群的2.49%）COVID-19检测呈阳性。脂肪肝患者（≥10%）检测呈阳性的风险增加（比值比：1.35，P = 0.007），而那些肥胖且患有脂肪肝的参与者，检测结果呈阳性时住院风险增加5.14倍（P = 0.0006）。英国生物银行的数据显示，患有脂肪性肝病的肥胖个体感染COVID-19和住院的风险增加。应考虑采取公共政策措施和个性化医疗，以保护这些高危个体。
